Peptides · Peptide comparison
Natriuretic Peptide (ANP) vs Thymosin Beta-4
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical data
Compound specifications
Natriuretic Peptide (ANP)
- Molecular formula
- C127H203N45O39S3
- Molecular weight
- 3080.5 g/mol
- Half-life
- Approximately 15-30 minutes (IV administration)
- Bioavailability
- 100% (intravenous administration)
- CAS number
- Variable depending on salt form; carperitide CAS: 120399-20-4
Thymosin Beta-4
- Molecular formula
- C212H350N56O78S
- Molecular weight
- 4963
- Half-life
- Dose-dependent (increases with higher doses)
- Bioavailability
- 100% (subcutaneous and intravenous)
- CAS number
- 77591-33-4
Protocols
Dosing compared
Natriuretic Peptide (ANP)
Intravenous
- 0.0125 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursVery low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
- 0.025-0.050 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursGuideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
Thymosin Beta-4
Subcutaneous injection
- 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
- 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
- 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Applications
Best suited for
Natriuretic Peptide (ANP)
- Managing acute decompensated heart failure with fluid overload
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Relieving shortness of breath caused by pulmonary congestion
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Lowering elevated blood pressure in emergency cardiac situations
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Reducing the workload on the heart during acute episodes
- Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
- Post-Surgery Recovery
- Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
- Chronic Wound Management
- Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
- Tissue Regeneration
- Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety profile
Side effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research status
Safety & evidence
Natriuretic Peptide (ANP)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
Thymosin Beta-4
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Decision guide
Which is right for you?
Natriuretic Peptide (ANP)
Choose Natriuretic Peptide (ANP) if…
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Thymosin Beta-4
Choose Thymosin Beta-4 if…
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation